GLP3-R

Retatrutide is an investigational triple receptor agonist that targets GLP-1, GIP, and glucagon pathways. Researchers are interested in this peptide because it may have broad effects on appetite regulation, energy expenditure, body weight, and metabolic health.

Scientific Information

• Full Name: Retatrutide
• Structure: Retatrutide is a multi-agonist peptide designed to activate three different metabolic signaling pathways, making it distinct from single- or dual-pathway peptides.

Research & Potential Benefits

• • Body Weight Reduction Research:
    Early clinical studies suggest retatrutide may produce substantial reductions in body weight in adults with obesity. (Reference 1, 2)

• • Appetite & Eating Behavior Research:
    Researchers have also studied retatrutide for changes in eating behavior and appetite-related outcomes. (Reference 2, 3)

• • Metabolic Support:
    Retatrutide has been investigated for possible benefits in glucose regulation and other metabolic markers. (Reference 1, 4)

• Body Composition Research:
  Newer studies suggest retatrutide may improve fat-mass reduction while maintaining a lean-mass-loss proportion similar to other obesity therapies. (Reference 3, 4)

References

1. Jastreboff, A.M. et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity.” New England Journal of Medicine.
2. Ray, A. et al. “Retatrutide: a triple incretin receptor agonist for obesity and type 2 diabetes.” Expert Opinion on Investigational Drugs.
3. Goetz, I.A. et al. “Perceived benefits of treatment for obesity with retatrutide.” Obesity Science & Practice.
4. Coskun, T. et al. “Effects of retatrutide on body composition in people with type 2 diabetes.” Diabetes, Obesity and Metabolism.

Disclaimer

For Research Use Only. Not for human consumption.